Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Hill on the Potential Utility of Next-Generation PI3K Inhibitors in CLL

February 9th 2022

Brian T. Hill, MD, PhD, discusses the potential utility of next-generation PI3K inhibitors in chronic lymphocytic leukemia.

Challenges Continued

February 4th 2022

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges.

FDA Investigates Potential Increased Risk of Death With Umbralisib in Select Lymphomas

February 4th 2022

The FDA has announced that they are investigating umbralisib (Ukoniq), an oral inhibitor of PI3K-delta and CK1-epsilon that is approved to treat patients with marginal zone lymphoma and follicular lymphoma, after initial data from the phase 3 UNITY-CLL trial revealed a potential increased risk of death in those who received the agent.

Challenges With BTK Inhibitors

February 4th 2022

Dr Lamanna explains the challenges associated with BTK inhibitors.

Acalabrutinib Shows Better Safety, Tolerability Than Ibrutinib in Relapsed/Refractory CLL

February 4th 2022

John Seymour, MD, discusses the safety of acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia, and what findings from post-hoc analyses of the ELEVATE-RR trial mean for clinical practice.

Dr. Melenhorst on the Persistence of CD4+ CAR T-Cells in Inducing Remissions in CLL

February 2nd 2022

Jan Joseph Melenhorst, BSc, MS, PhD, discusses the persistence of CD4+ CAR T-cells in inducing remissions in patients with chronic lymphocytic leukemia.

Zanubrutinib sNDA for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Accepted in China

February 1st 2022

The China National Medical Products Administration has accepted a supplemental new drug application for zanubrutinib as a treatment option for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Chronic Lymphocytic Leukemia Treatment Landscape

January 28th 2022

Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the chronic lymphocytic leukemia treatment (CLL) landscape, including risk factors and treatment options.

Dr. Choi on Future Research Directions in CLL

January 17th 2022

Michael Choi, MD, discusses future research directions in chronic lymphocytic leukemia.

Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL

January 17th 2022

Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

Subcutaneous Epcoritamab Demonstrates Early Activity, Favorable Tolerability in CLL

January 16th 2022

Subcutaneous epcoritamab demonstrated early activity and favorable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia and high-risk features.

Ibrutinib Increases Risk of Select Cardiovascular AEs in Patients With Chronic Lymphocytic Leukemia

January 14th 2022

Treatment with ibrutinib in patients with chronic lymphocytic leukemia was linked with increased risk of cardiovascular adverse effects like atrial fibrillation, hospital-diagnosed bleeding, and heart failure, but was not linked with a higher risk of acute myocardial infarction or stroke.

Dr. Danilov on the Reduced Use of Chemoimmunotherapy in CLL

January 14th 2022

Alexey V. Danilov, MD, PhD, discusses the reduced use of chemoimmunotherapy in chronic lymphocytic leukemia.

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th 2022

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Zanubrutinib Improves PFS in Treatment-Naïve CLL/SLL

January 14th 2022

Zanubrutinib elicited a statistically significant improvement in progression-free survival vs the combination of bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burger on the Benefits of Novel Combination Approaches in CLL

January 13th 2022

Jan A. Burger, MD, PhD, discusses the benefit of combination therapy in patients with chronic lymphocytic leukemia.

Dr. Brander on the Role of MRD Negativity With Venetoclax-Based Regimens in CLL

January 13th 2022

Danielle M. Brander, MD, discusses the role of achieving minimal residual disease negativity with venetoclax-based regimens in chronic lymphocytic leukemia.

Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12th 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Seymour on the Safety of Acalabrutinib Vs Ibrutinib in Relapsed/Refractory CLL

January 10th 2022

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Choi on the Long-Term Efficacy of Frontline Ibrutinib in CLL

January 6th 2022

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.